BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
2 Kang BK, Kim JH, Kim KM, Ko GY, Yoon HK, Gwon DI, Sung KB. Transcatheter arterial chemoembolization for hepatocellular carcinoma after attempted portal vein embolization in 25 patients. AJR Am J Roentgenol. 2009;193:W446-W451. [PMID: 19843726 DOI: 10.2214/AJR.09.2479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
3 Okamura S, Shimose S, Niizeki T, Kamachi N, Noda Y, Shirono T, Iwamoto H, Nakano M, Kuromatsu R, Koga H, Torimura T. Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. Mol Clin Oncol 2022;16:8. [PMID: 34881028 DOI: 10.3892/mco.2021.2442] [Reference Citation Analysis]
4 Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623-1641. [PMID: 18925854 DOI: 10.1586/14737140.8.10.1623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
5 Cho WC, Chen HY. Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis. Expert Opin Investig Drugs. 2009;18:617-635. [PMID: 19388879 DOI: 10.1517/13543780902855308] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
6 Yoon H, Kim J, Kim K, Lee I, Ko G, Song H, Gwon D. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clinical Radiology 2010;65:271-7. [DOI: 10.1016/j.crad.2010.01.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, Di Piazza S, Marrone C, Orlando A, Fusco G. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis. 2010;42:515-519. [PMID: 19914153 DOI: 10.1016/j.dld.2009.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
8 Kim JH, Yoon H, Ko G, Gwon DI, Jang CS, Song H, Shin JH, Sung K. Nonresectable Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Analysis of the Response and Prognostic Factors after Transcatheter Arterial Chemoembolization. Radiology 2010;255:270-7. [DOI: 10.1148/radiol.09091076] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 5.1] [Reference Citation Analysis]
9 Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 2009;29:1291-1298. [PMID: 19392861 DOI: 10.1111/j.1365-2036.2009.04016.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol. 2011;80:40-53. [PMID: 21067940 DOI: 10.1016/j.critrevonc.2010.10.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
11 Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol. 2011;22:917-923. [PMID: 21571545 DOI: 10.1016/j.jvir.2011.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 5.5] [Reference Citation Analysis]
12 Morse MA, Hanks BA, Suhocki P, Doan PL, Liu EA, Frost P, Bernard SA, Tsai A, Moore DT, O'neil BH. Improved Time to Progression for Transarterial Chemoembolization Compared With Transarterial Embolization for Patients With Unresectable Hepatocellular Carcinoma. Clinical Colorectal Cancer 2012;11:185-90. [DOI: 10.1016/j.clcc.2011.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
13 Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH, Song HY. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113:1614-1622. [PMID: 18704990 DOI: 10.1002/cncr.23787] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
14 Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. J Vasc Interv Radiol. 2014;25:371-378. [PMID: 24468045 DOI: 10.1016/j.jvir.2013.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Barman PM, Sharma P, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci. 2014;59:2821-2825. [PMID: 24973040 DOI: 10.1007/s10620-014-3247-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Park YS, Kim JH, Kim KW, Lee IS, Yoon HK, Ko GY, Sung KB. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol. 2009;64:779-785. [PMID: 19589416 DOI: 10.1016/j.crad.2009.02.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]